Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

Sulbactam-durlobactam is being developed for the treatment of infections caused by Acinetobacter baumannii, including those caused by multidrug- and carbapenem-resistant isolates. This was a phase 1 study to evaluate the effects of various degrees of renal impairment, including subjects with end-sta...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, John, Preston, Richard A., Mamikonyan, Grigor, Stone, Emily, Isaacs, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709459/
https://www.ncbi.nlm.nih.gov/pubmed/31307978
http://dx.doi.org/10.1128/AAC.00794-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709459/
https://www.ncbi.nlm.nih.gov/pubmed/31307978
http://dx.doi.org/10.1128/AAC.00794-19

Ejemplares similares